ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry Liebman who wrote (189)	11/11/1997 2:58:00 AM
From: John Dwyer	Read Replies (2) of 4474

Hi all, Did anybody see the press releases from Cell Genesis a week or so ago? They demonstrated effective gene delivery and stable protein production in skeletal muscle tissue for more than six months using the AAV vector delivery system. They also released results of their second generation lentivirus vector and showed long-term, stable expression in liver and muscle tissue. This is further proof-of-principle of Ariad's regulated gene therapy approach. Genovo uses several viral (and non-viral) delivery systems, including AAV, and so it would seem that these results from CEGE argue that Ariad's program could be quite successful. John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next